ClinConnect ClinConnect Logo
Search / Trial NCT05972174

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

Launched by MODERNATX, INC. · Jul 25, 2023

Trial Information

Current as of June 05, 2025

Completed

Keywords

Influenza Vaccine Moderna M Rna 1018 Virus Diseases Vaccines Pandemic Influenza

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and results of electrocardiogram testing.
  • Body mass index of 18 kilograms (kg)/square meter (m\^2) to 39 kg/m\^2 (inclusive) at the Screening visit.
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception, and not currently breastfeeding.
  • Key Exclusion Criteria:
  • Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius \[°C\]/100.4 degrees Fahrenheit \[°F\]) 72 hours prior to or at the Screening Visit or Day 1.
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Participant has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 180 days prior to Screening Visit (for corticosteroids ≥10 milligrams \[mg\]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Participant has received any vaccine authorized or approved by local health agency including mRNA vaccine ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention.
  • Participant has participated in an interventional clinical study within 28 days prior to the Screening visit based on the medical history interview or plans to do so while participating in this study.
  • Other inclusion/exclusion criteria may apply.

About Modernatx, Inc.

ModernaTX, Inc. is a pioneering biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Established with a commitment to addressing unmet medical needs, Moderna leverages its proprietary platform to create innovative therapies and vaccines for a variety of diseases, including infectious diseases and cancer. The company gained global recognition for its rapid development of an mRNA-based COVID-19 vaccine, showcasing its agility and expertise in the biopharmaceutical landscape. Through robust clinical trials and a commitment to scientific excellence, ModernaTX aims to redefine the future of medicine and enhance patient outcomes worldwide.

Locations

Southampton, England, United Kingdom

London, , United Kingdom

London, , United Kingdom

Lenexa, Kansas, United States

Tomball, Texas, United States

London, , United Kingdom

London, , United Kingdom

South Jordan, Utah, United States

Newcastle Upon Tyne, England, United Kingdom

Hollywood, Florida, United States

Sugar Land, Texas, United States

Southfield, Michigan, United States

Savannah, Georgia, United States

Lincoln, Nebraska, United States

East Greenwich, Rhode Island, United States

Birmingham, London, United Kingdom

Bradford, London, United Kingdom

Bristol, London, United Kingdom

Cardiff, London, United Kingdom

Salford, London, United Kingdom

Truro, London, United Kingdom

Wrexham, London, United Kingdom

Norwich, Norfolk, United Kingdom

Corby, Northamptonshire, United Kingdom

Edinburgh, , United Kingdom

London, , United Kingdom

North Finchley, , United Kingdom

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported